Operating And Business Equipment Operating And Business Equipment [Member] Operating And Business Equipment Classes of financial liabilities [axis] Classes of financial liabilities [axis] Associates [axis] Associates [axis] Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] Total other operating result Other operating income (expense) Recognized directly in equity Deferred tax relating to items credited (charged) directly to equity Cover [Abstract] Recognized directly in equity Increase (decrease) through business combinations, deferred tax liability (asset) Sale Of Stock [Domain] Sale Of Stock [Domain] Sale Of Stock [Domain] Average price paid per ADS (in dollar per share and euro per share) Share Repurchase Program, Average Price Per American depositary Share (ADS) Share Repurchase Program, Average Price Per American depositary Share (ADS) Total current liabilities Current liabilities Summary of Expense Recognized for Employee Services Received Explanation of effect of share-based payments on entity's profit or loss [text block] BioNTech Europe GmbH BioNTech Europe GmbH [Member] BioNTech Europe GmbH Trading Symbol Trading Symbol Earnings per Share Disclosure of earnings per share [text block] Statement of changes in equity [abstract] Non-current obligations under lease contracts Noncurrent Obligations Under Lease Contracts [Member] Noncurrent Obligations Under Lease Contracts Ordinary shares Ordinary shares [member] Amounts included in contract liabilities at the beginning of the year Revenue that was included in contract liability balance at beginning of period Classes of intangible assets and goodwill [axis] Classes of intangible assets and goodwill [axis] Net gain / (loss) on equity instruments designated at fair value through other comprehensive income Other comprehensive income, net of tax, gains (losses) from investments in equity instruments Liabilities arising from financing activities Liabilities arising from financing activities [domain] BioNTech Diagnostics GmbH BioNTech Diagnostics GmbH [Member] BioNTech Diagnostics GmbH Summary of Number and Weighted-Average Exercise Price of Share Options Disclosure of number and weighted average exercise prices of share options [text block] Earnings per share [line items] Earnings per share [line items] thereof allocated and un-vested (in shares) Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement Cash outflow to tax authority Cash Outflow To Tax Authority Cash Outflow To Tax Authority Other revenues Commercial [Member] Commercial Share Repurchase Program, Tranche Two Share Repurchase Program, Tranche Two [Member] Share Repurchase Program, Tranche Two Number shares vested (in shares) Number of option rights vested (in shares) Number of other equity instruments exercised or vested in share-based payment arrangement Option to purchase ordinary shares (in shares) Number of instruments granted in share-based payment arrangement Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets Non-current Non-Currnet Contract Assets [Roll Forward] Non-Currnet Contract Assets Provisions Disclosure of provisions [text block] Cost of sales Cost of sales [member] Major customers Major customers [domain] Types of risks Types of risks [domain] Additions Increase (Decrease) In Current Contract Assets Increase (Decrease) In Current Contract Assets Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [table] Total non-current liabilities Non-current liabilities Unfinished goods Current work in progress United States United States UNITED STATES Finished goods Current finished goods BioNTech Research and Development, Inc. BioNTech Research and Development, Inc. [Member] BioNTech Research and Development, Inc. Production facilities Production Facilities [Member] Production Facilities Discount rate Discount rate, measurement input [member] Other intangible assets Beginning balance Ending balance Intangible assets and goodwill Changes in scope of consolidation Changes In Scope Of Consolidation Of Contract Assets Changes In Scope Of Consolidation Of Contract Assets Purchase of intangible assets and right-of-use assets Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities 2024 North America Employee Participation Plan 2024 North America Employee Participation Plan [Member] 2024 North America Employee Participation Plan Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets Significant unobservable input, assets Significant unobservable input, assets Cost of sales Cost of sales Cost of sales Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements Disclosure of fair value measurement of liabilities [text block] Loans and borrowings Interest Bearing Loans And Borrowings Interest Bearing Loans And Borrowings Business Combinations and Goodwill Description of accounting policy for business combinations and goodwill [text block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Federal tax credits Accumulated Tax Losses In Federal Tax Credits Accumulated Tax Losses In Federal Tax Credits Total Other non-financial liabilities Trade payables and other payables Trade and other current payables Expected life (in years) Option life, share options granted Cash outflow Expense from share-based payment transactions Options outstanding, weighted-average expected life (in years) Weighted average remaining contractual life of outstanding share options Losses on litigation settlements Losses on litigation settlements Reclassifications Increase (decrease) through transfers and other changes, intangible assets and goodwill Depreciation Depreciation, property, plant and equipment Maximum cash payment Maximum Cash Payment In Share-Based Payment Arrangement Maximum Cash Payment In Share-Based Payment Arrangement Redemption of convertible note Redemption Of Convertible Note Redemption Of Convertible Note Other Customers Other Customers [Member] Other Customers Increase (decrease) in intangible assets Increase (decrease) in intangible assets and goodwill Disclosure of financial liabilities [table] Disclosure of financial liabilities [table] Classes of intangible assets and goodwill Classes of intangible assets and goodwill [domain] Sean Marett Sean Marett [Member] Sean Marett Net cash flows used in investing activities Cash flows from (used in) investing activities Types of risks [axis] Types of risks [axis] Other financial liabilities Other Financial Liabilities [Member] Other Financial Liabilities Sales and marketing expenses Sales And Marketing Expense [Member] Sales And Marketing Expense Amortized Cost Amortized Cost [Member] Amortized Cost As of January 1 As of December 31 Contract assets Expense / (Income) arising from cash-settled share-based payment arrangements Expense from cash-settled share-based payment transactions Impairment Impairment loss recognised in profit or loss, property, plant and equipment Summary of Inputs Used in Measurement of Fair Value at Grant Date Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Foreign exchange differences, net Net foreign exchange gain Level 2 (Fair value) Level 2 of fair value hierarchy [member] Document Registration Statement Document Registration Statement Intangible Assets Description of accounting policy for intangible assets and goodwill [text block] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Revenue from Contracts with Customers Description of accounting policy for recognition of revenue [text block] Level 1 (Fair value) Level 1 of fair value hierarchy [member] Interest received and realized gains from cash and cash equivalents Interest received, classified as operating activities Pension costs Post-employment benefit expense in profit or loss, defined benefit plans Payment terms in contracts with customers Description of significant payment terms in contracts with customers Lease liabilities Lease liabilities [member] Other operating income Miscellaneous other operating income Assets Assets [abstract] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Lease liabilities Lease liabilities Lease liabilities Disclosure of financial assets [line items] Disclosure of financial assets [line items] Components of equity [axis] Components of equity [axis] Phantom shares awarded (in shares) Key Management Personnel Compensation, Phantom Shares Awarded Key Management Personnel Compensation, Phantom Shares Awarded Deviation due to deviating income tax rate (Germany and foreign countries) Tax effect of foreign tax rates List Of Accounting Policies [Abstract] List Of Accounting Policies [Abstract] List Of Accounting Policies [Abstract] Contractual obligation to acquire intangible assets Contractual commitments for acquisition of intangible assets Temporary difference, unused tax losses and unused tax credits Temporary difference, unused tax losses and unused tax credits [domain] reSano GmbH reSano GmbH [Member] reSano GmbH Non-current Non-Current Contract Liabilities [Roll Forward] Non-Current Contract Liabilities BioNTech Idar-Oberstein Services GmbH BioNTech Idar-Oberstein Services GmbH [Member] BioNTech Idar-Oberstein Services GmbH Biopharma BioNTech Israel Ltd. Biopharma BioNTech Israel Ltd. [Member] Biopharma BioNTech Israel Ltd. Summary of Detailed Information About Intangible Assets Disclosure of reconciliation of changes in intangible assets and goodwill [text block] Schedule of Other Financial Commitments Disclosure of commitments [text block] Net cash flows from operating activities Cash flows from (used in) operating activities Share-based payments Increase (decrease) through share-based payment transactions, equity Sale Of Stock [Axis] Sale Of Stock [Axis] Sale Of Stock Non tax-effective share-based payment expenses Non-Recognition Of Tax Effect On Share-Based Payment Expenses Non-Recognition Of Tax Effect On Share-Based Payment Expenses Adjustments to reconcile profit before tax to net cash flows: Adjustments to reconcile profit (loss) [abstract] Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [axis] Transaction costs Share issue related cost Expected volatility Expected volatility, share options granted Insurance Obligation And Service Contracts Insurance Obligation And Service Contracts [Member] Insurance Obligation And Service Contracts Contact Personnel Name Contact Personnel Name -5 % Negative Five Percentage Change In Foreign Exchange Rate [Member] Negative Five Percentage Change In Foreign Exchange Rate Right-of-use assets Right-of-use assets Total liabilities Liabilities Summary of Employee Benefits Expense Disclosure Of Detailed Information About Employee Benefits Expense Explanatory [Table Text Block] Disclosure Of Detailed Information About Employee Benefits Expense Explanatory Software Computer software [member] Shares issued (in shares) Number of shares issued Contract Liabilities [Roll Forward] Contract Liabilities [Roll Forward] Contract Liabilities Vesting percentage Annual Vesting Percentage Of Share Based Payment Arrangement Annual Vesting Percentage Of Share Based Payment Arrangement Other financial liabilities Other financial liabilities Cash And Cash Equivalents [Table] Cash And Cash Equivalents [Table] Cash And Cash Equivalents [Table] Total Beginning balance Ending balance Financial liabilities Financial liabilities Categories of financial assets [abstract] Categories of financial assets [abstract] CGU External Business of InstaDeep External Business of InstaDeep [Member] External Business of InstaDeep Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expenses Description of accounting policy for research and development expense [text block] Gross carrying amount Gross carrying amount [member] Reclassifications Reclassifications Of Property, Plant And Equipment Reclassifications Of Property, Plant And Equipment Issued Capital and Reserves Disclosure of share capital, reserves and other equity interest [text block] Document Type Document Type Loss on derivative instruments at fair value through profit or loss Loss On Derivative Instruments At Fair Value [Member] Loss On Derivative Instruments At Fair Value Security investments disclosed as cash and cash equivalents Cash equivalents Non-deductible expenses Tax Effect Of Expense Not Deductible In Determining Taxable Profit (Tax Loss), Net Of Addiitonal Deductions Tax Effect Of Expense Not Deductible In Determining Taxable Profit (Tax Loss), Net Of Addiitonal Deductions Awards paid one year after reaching target Percentage Of American Depository Shares To Ordinary Shares Percentage Of American Depository Shares To Ordinary Shares Employee Stock Option Plan Employee Stock Option Plan [Member] Employee Stock Option Plan Maximum Maximum [Member] Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [table] New Technologies Re​ New Technologies Re​ [Member] New Technologies Re​ thereof un-vested (in shares) Number Of Share Options Unested In Share-Based Payment Arrangement Number Of Share Options Unested In Share-Based Payment Arrangement Minimum Bottom of range [member] Property, Plant and Equipment Description of accounting policy for property, plant and equipment [text block] Litigation Settlment, Contribution To Research And Development Litigation Settlment, Contribution To Research And Development Litigation Settlment, Contribution To Research And Development BioNTech Innovation and Services Marburg GmbH BioNTech Innovation and Services Marburg GmbH [Member] BioNTech Innovation and Services Marburg GmbH Disclosure of reconciliation of liabilities arising from financing activities [table] Disclosure of reconciliation of liabilities arising from financing activities [table] BioNTech USA Holding, LLC BioNTech USA Holding, LLC [Member] BioNTech USA Holding, LLC Statistical Measurement [Axis] Statistical Measurement [Axis] Other Provisions Other Provisions [Member] Other Provisions Disclosure of non-adjusting events after reporting period [table] Disclosure of non-adjusting events after reporting period [table] Attribution of expenses by nature to their function [domain] Attribution of expenses by nature to their function [domain] Classes of liabilities [axis] Classes of liabilities [axis] Finance income Finance income Finance income Title and Position [Axis] Title and Position [Axis] Disclosure Of Income And Expenses [Table] Disclosure Of Income And Expenses [Table] Disclosure Of Income And Expenses Effective exercise price maximum (in dollars per share) Effective Exercise Price Maximum Effective Exercise Price Maximum Classes of financial instruments Classes of financial instruments [domain] Business combinations [axis] Business combinations [axis] Corporate tax rate (as a percent) Corporate Tax Rate Corporate Tax Rate Summary of Goodwill Recognized Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory [Table Text Block] Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory Forecast Forecast [Member] Assets [Roll Forward] Assets [Roll Forward] Assets Counterparty Name [Domain] Counterparty Name [Domain] Construction in progress and advance payments Construction In Progress And Advance Payments [Member] Construction In Progress And Advance Payments Recognition as revenues Decrease through performance obligation being satisfied, contract liabilities Major customers [axis] Major customers [axis] BioNTech Pharmaceuticals Spain S.L BioNTech Pharmaceuticals Spain S.L [Member] BioNTech Pharmaceuticals Spain S.L Ownership [Axis] Ownership [Axis] Weighted average fair value Weighted average fair value at measurement date, share options granted Employee Stock Ownership Plan 2020 Employee Stock Ownership Plan 2020 [Member] Employee Stock Ownership Plan 2020 Carrying amount Carrying amount [member] Exercise price in translation for IPO (in dollar per share and euro per share) Exercise Price Currency Translation Of Public Offering Price Per Share Exercise Price Currency Translation Of Public Offering Price Per Share Disclosure of reconciliation of liabilities arising from financing activities [line items] Disclosure of reconciliation of liabilities arising from financing activities [line items] Classes of financial assets [axis] Classes of financial assets [axis] Employee Stock Ownership Plan 2018 Employee Stock Ownership Plan 2018 [Member] Employee Stock Ownership Plan 2018 Additions Additions other than through business combinations, intangible assets other than goodwill thereof vested (in shares) Number Of Share Options Vested In Share-Based Payment Arrangement Number Of Share Options Vested In Share-Based Payment Arrangement Foreign Currencies Description of accounting policy for foreign currency translation [text block] Levels of fair value hierarchy [axis] Levels of fair value hierarchy [axis] Classes of property, plant and equipment [domain] Classes of property, plant and equipment [domain] Current liabilities Current liabilities [abstract] Recognized in P&L Deferred tax expense (income) recognised in profit or loss Goodwill Goodwill Share-based payments Types of share-based payment arrangements [domain] InstaDeep France SAS InstaDeep France SAS [Member] InstaDeep France SAS Gains from financial instruments measured at fair value Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value Other effects Other tax effects for reconciliation between accounting profit and tax expense (income) Simba Merger Sub Simba Merger Sub [Member] Simba Merger Sub Subsidiaries [domain] Subsidiaries [domain] Basis of Preparation Statement of IFRS compliance [text block] Dividends Dividends paid, classified as financing activities Dividends paid, classified as financing activities Net amount spend Share Repurchase Program, Net Amount Spent Share Repurchase Program, Net Amount Spent Interest paid and realized losses from cash and cash equivalents Interest paid, classified as operating activities thereof: attributable to performance obligations satisfied in prior periods Current Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Current Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Change in valuation allowance Tax Effect Of Change In Valuation Allowance Tax Effect Of Change In Valuation Allowance Intrinsic value of exercised options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value1 Document Shell Company Report Document Shell Company Report Increase (Decrease) In Contract Assets Increase (Decrease) In Contract Assets Increase (Decrease) In Contract Assets Scenario [Domain] Scenario [Domain] Threshold amount of dividend by number of shares outstanding immediately following initial public offering Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering Share-Based Payments Description of accounting policy for share-based payment transactions [text block] JPT Peptide Technologies Inc. JPT Peptide Technologies Inc. [Member] JPT Peptide Technologies Inc. Provisions Description of accounting policy for provisions [text block] Sales and marketing expenses Sales and marketing expenses Sales and marketing expense Beginning balance, number of ordinary shares underlying options (in shares) Ending balance, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Outstanding Number Of Ordinary Shares Underlying Options Outstanding Disclosure of Contract Assets Disclosure Of Contract Assets [Table Text Block] Disclosure Of Contract Assets Remeasurement gain / (loss) on defined benefit plans Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Other reserves Other reserves [member] Total compensation of key management personnel Key management personnel compensation Upfront payment, acquisition of intangible asset Upfront Payment, Acquisition of Intangible Asset Upfront Payment, Acquisition of Intangible Asset Other non-financial liabilities Total current Other current non-financial liabilities Weighted average exercise price (€) Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Money market funds Money Market Fund [Member] Money Market Fund Classes of financial liabilities Classes of financial liabilities [domain] State tax credits Accumulated Tax Losses In State Tax Credits Accumulated Tax Losses In State Tax Credits Percentage of target share price applicable for prior twelve month period (as a percent) Percentage Of Target Share Price Applicable For Prior Twelve Month Percentage Of Target Share Price Applicable For Prior Twelve Month Intangible assets other than goodwill [member] Intangible assets other than goodwill [member] Summary of Property, Plant and Equipment Disclosure of detailed information about property, plant and equipment [text block] Simba Merger Sub BioNTech (Shanghai) Pharmaceuticals Co. Ltd. [Member] BioNTech (Shanghai) Pharmaceuticals Co. Ltd. Significant unobservable input, liabilities Significant unobservable input, liabilities Net profit / (loss) Net profit / (loss) Profit (loss) Currency [Axis] Currency [Axis] Adjustment prior year taxes Adjustments for current tax of prior periods Loans and borrowings Loans And Borrowings [Member] Loans And Borrowings Treasury shares Treasury shares [member] Timing of transfer of goods or services [axis] Timing of transfer of goods or services [axis] Prepayments related to service contracts Current Prepayments Related To Service Contracts Current Prepayments Related To Service Contracts BioNTech Real Estate Verwaltungs GmbH BioNTech Real Estate Verwaltungs GmbH [Member] BioNTech Real Estate Verwaltungs GmbH Current Current Contract Assets [Roll Forward] Current Contract Assets Advance payments Advance Payments [Member] Advance Payments Exchange differences on translation of foreign operations Other comprehensive income, net of tax, exchange differences on translation of foreign operations Associates [domain] Associates [domain] Statement of comprehensive income [abstract] thereof vested, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement Number of share options exercisable in share-based payment arrangement (in shares) Number of share options exercisable in share-based payment arrangement Disclosure Of Corporate Information Explanatory [Abstract] Disclosure Of Corporate Information Explanatory [Abstract] Disclosure Of Corporate Information Explanatory [Abstract] Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory [Table Text Block] Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory Document Accounting Standard Document Accounting Standard Other operating equipment Other Operating Equipment [Member] Other Operating Equipment Exercise price (in euros per share) Exercise price, share options granted Acquisition of subsidiaries and businesses Acquisitions through business combinations, intangible assets and goodwill Diluted earnings for the period per share (in euros per share) Diluted profit for the period per share (in euros per share) Diluted earnings (loss) per share Tax losses Unused tax losses [member] Significant Accounting Policies Disclosure of material accounting policy information [text block] Property, plant and equipment, useful life (in years) Useful life measured as period of time, property, plant and equipment Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Summary of Cash and Cash Equivalents Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block] Disclosure Of Cash And Cash Equivalents Explanatory Disclosure of other provisions [line items] Disclosure of other provisions [line items] Royalty Assets Royalty Assets [Member] Royalty Assets Proposed dividends per share (in euros per share) Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share Provisions Total current Current provisions Summary of Revenue Recognized Disclosure Of Recognition Of Revenue Explanatory [Table Text Block] Disclosure Of Recognition Of Revenue Explanatory Finance expense excluding foreign exchange differences Adjustments for finance costs Provisions Total non-current Non-current provisions Share Repurchase Program, Tranche One Share Repurchase Program, Tranche One [Member] Share Repurchase Program, Tranche One Reclassifi-cation Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities Disclosure of non-adjusting events after reporting period [line items] Disclosure of non-adjusting events after reporting period [line items] Contract liabilities Contract Liabilities [Member] Contract Liabilities Other Non-Financial Liabilities [Abstract] Other Non-Financial Liabilities Net gain / (loss) on equity instruments designated at fair value through other comprehensive income Financial assets at fair value through other comprehensive income, category [member] Share repurchase program Share Repurchase Program Classified As Financing Activities Share Repurchase Program Classified As Financing Activities COVID-19 vaccine revenues COVID-19 Vaccine Revenues [Member] COVID-19 Vaccine Revenues Summary of Information about Entity with Significant Influence Over Group Disclosure Of Entity With Significant Influence Over Group Explanatory [Table Text Block] Disclosure Of Entity With Significant Influence Over Group Explanatory Other financial liabilities Other current financial liabilities Granted (in euros per share) Weighted average exercise price of other equity instruments granted in share-based payment arrangement Current Current financial liabilities InstaDeep Tunisia SARL InstaDeep Tunisia SARL [Member] InstaDeep Tunisia SARL Current obligations under lease contracts Current Obligations Under Lease Contracts [Member] Current Obligations Under Lease Contracts Property, plant and equipment [member] Property, plant and equipment [member] Commitments under purchase agreements for property, plant and equipment Contractual commitments for acquisition of property, plant and equipment Summary of Transactions Between Other Related Parties Disclosure of transactions between related parties [text block] Changes in scope of consolidation Changes In Scope Of Consolidation Of Current Contract Assets Changes In Scope Of Consolidation Of Current Contract Assets Local Phone Number Local Phone Number Payments related to lease liabilities Payments of lease liabilities, classified as financing activities Social security costs Social security contributions Purchase of shares under agreement (in shares) Purchase Of Shares Under Agreement Purchase Of Shares Under Agreement Total current assets Current assets BioNTech Innovation GmbH BioNTech Innovation GmbH [Member] BioNTech Innovation GmbH Fixed assets Fixed Assets [Member] Fixed Assets Weighted average share price (in euros per share) Weighted average share price Disclosure of reserves within equity [line items] Disclosure of reserves within equity [line items] BioNTech Delivery Technologies GmbH BioNTech Delivery Technologies GmbH [Member] BioNTech Delivery Technologies GmbH Non-current Non-current financial liabilities Cash-settled option rights, exercised (in shares) Share options, exercised (in shares) Number of share options exercised in share-based payment arrangement Granted (in shares) Number of other equity instruments granted in share-based payment arrangement Events After the Reporting Period Disclosure of events after reporting period [text block] Raw materials and supplies Current raw materials and current production supplies Categories of financial assets Categories of financial assets [domain] Additions Purchases, fair value measurement, assets Other related parties Other related parties [member] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. [Member] BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. Other Intangible Assets and Goodwill Disclosure of intangible assets and goodwill [text block] +5 % Positive Five Percentage Change In Foreign Exchange Rate [Member] Positive Five Percentage Change In Foreign Exchange Rate AT Impf GmbH AT Impf GmbH [Member] AT Impf GmbH Disposals Disposals, property, plant and equipment Subsidiaries [axis] Subsidiaries [axis] Leases Description of accounting policy for leases [text block] CGU External Product Sales of JPT External Product Sales To JPT [Member] External Product Sales To JPT Property, Plant and Equipment Disclosure of property, plant and equipment [text block] U.S. dollar United States of America, Dollars Total depreciation charge Depreciation, right-of-use assets Grants Government grants Property, plant and equipment Property, plant and equipment, beginning balance Property, plant and equipment, ending balance Property, plant and equipment Effects Reconciliation of accounting profit multiplied by applicable tax rates [abstract] Key management personnel compensation, signing bonus Key Management Personnel Compensation, Signing Bonus Key Management Personnel Compensation, Signing Bonus Cash Dividend Description of accounting policy for dividends [text block] Fixed compensation Key Management Personnel Compensation, Fixed Compensation Key Management Personnel Compensation, Fixed Compensation Current assets Current assets [abstract] Categories of related parties Categories of related parties [domain] Total Provisions Attribution of expenses by nature to their function [axis] Attribution of expenses by nature to their function [axis] BioNTech Australia Pty Ltd. BioNTech Australia Pty Ltd. [Member] BioNTech Australia Pty Ltd. Vesting period Share Based Vesting Period Share Based Vesting Period Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] City Area Code City Area Code Disclosure of subsidiaries [table] Disclosure of subsidiaries [table] Auditor Location Auditor Location Financial Liabilities at Fair Value Through Other Comprehensive Income, Category Financial Liabilities At Fair Value Through Other Comprehensive Income, Category [Member] Financial Liabilities At Fair Value Through Other Comprehensive Income, Category Foreign exchange differences, net Foreign Exchange Differences [Member] Foreign Exchange Differences Estimated milestone payment to be received Estimated Milestone Payment To Be Received At Contract Inception Estimated Milestone Payment To Be Received At Contract Inception Rest of the World Rest of the World [Member] Rest of the World Security Investments Disclosed As Cash And Cash Equivalents Security Investments Disclosed As Cash And Cash Equivalents [Member] Security Investments Disclosed As Cash And Cash Equivalents Cash-Settled Share-Based Payment Arrangement Cash-Settled Share-Based Payment Arrangement [Member] Cash-Settled Share-Based Payment Arrangement Deferred taxes Deferred tax expense (income) Other Other Current Assets, Other Other Current Assets, Other Statement of changes in equity [table] Statement of changes in equity [table] Share repurchase program authorized amount Share Repurchase Program Authorized Amount Share Repurchase Program Authorized Amount Change in cash and cash equivalents resulting from other valuation effects Effect Of Other Valuation Changes On Cash And Cash Equivalents Effect Of Other Valuation Changes On Cash And Cash Equivalents Currency effects Currency Effects Of Contract Liabilities Currency Effects Of Contract Liabilities Reclassification for share-based payment arrangement Reclassification Of Share-Based Payment Arrangement Reclassification Of Share-Based Payment Arrangement Level 3 (Fair value) Level 3 of fair value hierarchy [member] BioNTech Real Estate Holding GmbH BioNTech Real Estate Holding GmbH [Member] BioNTech Real Estate Holding GmbH Employee Equity Plan, Long-Term Incentive Plus Program Employee Equity Plan, Long-Term Incentive Plus Program [Member] Employee Equity Plan, Long-Term Incentive Plus Program Land and buildings Land and buildings [member] Total equity and liabilities Equity and liabilities Capital reserve Capital reserve Current Current Contract Liabilities [Roll Forward] Current Contract Liabilities Other Other Income Expense [Member] Other Income Expense Intangible Assets [Abstract] Intangible Assets [Abstract] Intangible Assets [Abstract] Disposals Disposals, intangible assets and goodwill Wages and salaries Wages and salaries Change in cash and cash equivalents resulting from exchange rate differences Effect of exchange rate changes on cash and cash equivalents Amendment Flag Amendment Flag Categories of financial assets [axis] Categories of financial assets [axis] Recognition as revenues Increase (Decrease) In Non-Current Contract Liabilities Increase (Decrease) In Non-Current Contract Liabilities Business Combinations [Abstract] Business Combinations 1 [Abstract] Business Combinations 1 InstaDeep RSU Program Employees InstaDeep RSU Program Employees [Member] InstaDeep RSU Program Employees Contract assets As of January 1 As of December 31 Non-current contract assets Additions Increase (Decrease) In Contract Liabilities Increase (Decrease) In Contract Liabilities CGU Immunotherapies CGU Immunotherapies [Member] CGU Immunotherapies Increase of research and development expense Increase (Decrease) Of Research And Development Expense Increase (Decrease) Of Research And Development Expense German Federal Ministry of Health German Federal Ministry of Health [Member] German Federal Ministry of Health Income taxes Income taxes Income taxes Tax expense (income) Entity Address, Postal Zip Code Entity Address, Postal Zip Code BioNTech UK Ltd. BioNTech UK Ltd. [Member] BioNTech UK Ltd. Other financial liabilities Other non-current financial liabilities Currency effects Currency Effects Of Non-Current Contract Liabilities Currency Effects Of Non-Current Contract Liabilities Summary of Amounts Recognized in Consolidated Statement of Operations Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory [Table Text Block] Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory Auditor Name Auditor Name Weighted average share price (in euros per share) Weighted average share price, share options granted Additions Additions other than through business combinations, property, plant and equipment Non-current Non-current financial assets Beginning balance Ending balance Liabilities arising from financing activities Total Expense recognized for employee services received Expense from share-based payment transactions with employees MediLink Therapeutics Co., Ltd MediLink Therapeutics Co., Ltd [Member] MediLink Therapeutics Co., Ltd Tax rate for deferred taxes (as a percent) Tax Rate On Deferred Taxes Tax Rate On Deferred Taxes Summary of Disaggregation of Revenues from Contracts with Customers Disclosure of disaggregation of revenue from contracts with customers [text block] Profit or loss [abstract] Standards Issued but Not Yet Effective Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory [Policy Text Block] Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory Significant Accounting Judgements, Estimates and Assumptions Disclosure of accounting judgements and estimates [text block] Reclassification from non-current to current Reclassification From Non-Current To Current, Non-Current Contract Liabilities Reclassification From Non-Current To Current, Non-Current Contract Liabilities Treasury shares Treasury shares BioNTech Taiwan Co. Ltd. BioNTech Taiwan Co. Ltd. [Member] BioNTech Taiwan Co. Ltd. Weighted average number of ordinary shares outstanding for basic EPS (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share Corporate tax Accumulated Tax Losses In Corporate Tax Accumulated Tax Losses In Corporate Tax Short-term incentive – first installment Key management personnel compensation, short-term employee benefits Foreign exchange differences, net Net foreign exchange loss Announcement Of Research, Development And Commercialization Collaboration Agreement Announcement Of Research, Development And Commercialization Collaboration Agreement [Member] Announcement Of Research, Development And Commercialization Collaboration Agreement DeepChain Technology DeepChain Technology [Member] DeepChain Technology 1 to 5 years Later than one year and not later than five years [member] Share-based payments (incl. long-term incentive) Key management personnel compensation, share-based payment Entity Listings [Line Items] Entity Listings [Line Items] Currency risk Currency risk [member] Additions Increase (Decrease) In Non-Current Contract Assets Increase (Decrease) In Non-Current Contract Assets Research and development expenses Research and development expenses Research and development expense Disclosure of transactions between related parties [line items] Disclosure of transactions between related parties [line items] Loans and borrowings Interest Bearing Loans And Borrowings [Member] Interest Bearing Loans And Borrowings Other variable compensation Key Management Personnel Compensation, Other Variable Compensation Key Management Personnel Compensation, Other Variable Compensation Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions Reclassification Io Trade Accounts Receivables, Contract Assets Reclassification Io Trade Accounts Receivables, Contract Assets Reclassification Io Trade Accounts Receivables, Contract Assets Treasury shares (in shares) Number Of Shares Held In Treasury Number Of Shares Held In Treasury Minimum strike price (as a percent) Exercise Of Option Rights, Minimum Strike Price Percent Exercise Of Option Rights, Minimum Strike Price Percent Profit / (Loss) before tax Profit / (Loss) before tax Profit / (Loss) before tax Profit (loss) before tax Proceeds from sale of property, plant and equipment Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities Cash at banks and on hand Cash At Banks And On Hand [Member] Cash At Banks And On Hand Goods and services transferred over time Goods or services transferred over time [member] Total Contractual capital commitments Other non-financial liabilities Total non-current Other non-current non-financial liabilities Disclosure of contingent liabilities [line items] Disclosure of contingent liabilities [line items] Listed equity investments Listed Equity Investments [Member] Listed Equity Investments Statutory tax rate (as a percent) Applicable tax rate Increase of general and administrative expense Increase (Decrease) Of General And Administrative Expense Increase (Decrease) Of General And Administrative Expense Entity File Number Entity File Number Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Name Taxes Description of accounting policy for income tax [text block] Entity Address, Address Line One Entity Address, Address Line One Classes of assets [domain] Classes of assets [domain] Valuation adjustment Valuation Adjustment [Member] Valuation Adjustment Cash and Cash Equivalents Description of accounting policy for determining components of cash and cash equivalents [text block] Summary of Significant Unobservable Inputs Used in Fair Value Measurement Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block] Classes of assets [axis] Classes of assets [axis] Forfeited, weighted-average exercise price (in euros per share) Weighted average exercise price of share options forfeited in share-based payment arrangement Retained earnings Retained earnings [member] Price of ADS as a percentage of exercise price, maximum (as a percent) Price Of American Depository Share As A Percentage Of Exercise Price, Maximum Price Of American Depository Share As A Percentage Of Exercise Price, Maximum Issueance of share capital Issue of equity Share options outstanding (in shares) Beginning balance, share options (in shares) Ending balance, share options (in shares) (Phantom) share options outstanding (expected to be allocated) (in shares) Number of share options outstanding in share-based payment arrangement Total equity Equity at beginning of period Equity at end of period Equity Settled (in shares) Number Of Share Options Settled In Share-based Payment Arrangement Number Of Share Options Settled In Share-based Payment Arrangement Working capital adjustments: Working Capital Adjustments [Abstract] Working Capital Adjustments Increase of sales and marketing expense Increase (Decrease) Of Sales And Marketing Expense Increase (Decrease) Of Sales And Marketing Expense Obligations from onerous CMO contracts Current onerous contracts provision In-process R&D In Process R&D [Member] In Process R&D All Other Members All Other Members [Member] All Other Members Other revenues Other Sales [Member] Other Sales Disclosure of Provisions Disclosure Of Provisions [Table Text Block] Disclosure Of Provisions Total Intangible Assets With Indefinite Useful Life And Goodwill Intangible Assets With Indefinite Useful Life And Goodwill License And Option Agreement [Member] License And Option Agreement [Member] License And Option Agreement Finance income excluding foreign exchange differences Adjustments for finance income Option rights exercisable period (in years) Option Exercisable Period Option Exercisable Period Analysis of income and expense [abstract] Classes of financial instruments [axis] Classes of financial instruments [axis] Entity Filer Category Entity Filer Category Impairment loss recognised in profit or loss, intangible assets and goodwill Impairment Impairment loss recognised in profit or loss, intangible assets and goodwill Financial liabilities at amortised cost, category Financial liabilities at amortised cost, category [member] Categories of financial liabilities [abstract] Categories of financial liabilities [abstract] BioNTech Manufacturing GmbH BioNTech Manufacturing GmbH [Member] BioNTech Manufacturing GmbH 1 to 5 years Later than two years and not later than five years [member] Treasury Shares Description of accounting policy for treasury shares [text block] BioNTech Cell & Gene Therapies GmbH BioNTech Cell & Gene Therapies GmbH [Member] BioNTech Cell & Gene Therapies GmbH Statistical Measurement [Domain] Statistical Measurement [Domain] Reimbursement asset Reimbursement Asset [Member] Reimbursement Asset Disclosure of detailed information about business combination [line items] Disclosure of detailed information about business combination [line items] Earnings / (Loss) per share Earnings per share [abstract] Liability related to the phantom option awards Phantom Option Awards, Liability Phantom Option Awards, Liability Restricted share units Restricted share units [member] Intangible assets with indefinite useful life Intangible assets with indefinite useful life Cash And Cash Equivalents [Line Items] Cash And Cash Equivalents 1 [Line Items] Cash And Cash Equivalents 1 Share-based payments Share based Payments, Classified As Operating Activities Share based Payments, Classified As Operating Activities Summary of Financial Liabilities at Amortized Cost and at Fair Value through Profit or Loss Summary of Financial Liabilities at Amortized Cost Disclosure of financial liabilities [text block] Contact Personnel Fax Number Contact Personnel Fax Number Contractual disputes / settlements Legal proceedings provision Hedging instruments [axis] Hedging instruments [axis] Disclosure of financial assets [table] Disclosure of financial assets [table] Summary of Finance Income and Costs Disclosure Of Finance Income and Costs Explanatory [Table Text Block] Disclosure Of Finance Income and Costs Explanatory Research and development expenses Research And Development Expenses [Member] Research And Development Expenses Hedging instruments Hedging instruments [domain] Loss from financial instruments measured at amortized cost, expected credit losses Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost With Expected Credit Losses Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost With Expected Credit Losses Ordinary shares, no par value, with a notional amount attributable to each ordinary share of €1 Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share [Member] Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share Summary of Compensation of Key Management Personnel Disclosure of information about key management personnel [text block] Provision related to usage Current Onerous Contracts Provision, Related To Usage Current Onerous Contracts Provision, Related To Usage Consolidated structured entities [domain] Consolidated structured entities [domain] Reclassification from non-current to current Reclassification From Non-Current To Current, Contract Liabilities Reclassification From Non-Current To Current, Contract Liabilities Total Amounts payable, related party transactions Target incentive amount Share Based Compensation, Target Incentive Amount Share Based Compensation, Target Incentive Amount Applicable wage taxes and social security contributions resulting from and withheld upon exercise Payables on social security and taxes other than income tax Ryvu Therapeutics S.A. Ryvu Therapeutics S.A. [Member] Ryvu Therapeutics S.A. Contingencies And Other Financial Commitments [Abstract] Contingencies And Other Financial Commitments [Abstract] Contingencies And Other Financial Commitments [Abstract] Government Grants Description of accounting policy for government grants [text block] Management Board Management Board [Member] Management Board Other financial assets Other non-current financial assets Trade tax Accumulated Tax Losses In Trade Tax Accumulated Tax Losses In Trade Tax BioNTech Individualized mRNA Manufacturing GmbH BioNTech Individualized mRNA Manufacturing GmbH [Member] BioNTech Individualized mRNA Manufacturing GmbH Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Option term Option Term Option Term InstaDeep Employee Incentive Plan InstaDeep Employee Incentive Plan [Member] InstaDeep Employee Incentive Plan Medine GmbH Medine GmbH [Member] Medine GmbH Other Other finance cost Gain on derivative instruments at fair value through profit or loss Gain On Derivative Instruments At Fair Value Through Profit Or Loss [Member] Gain On Derivative Instruments At Fair Value Through Profit Or Loss Share Repurchase Program Period [Domain] Share Repurchase Program Period [Domain] Share Repurchase Program Period [Domain] Components of equity Components of equity [domain] Dividends Dividends recognised as distributions to owners Expense related to short-term leases and leases of low-value assets Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used Bad debt expense has been recognized Expense recognised during period for bad and doubtful debts for related party transaction Short-term incentive – second installment Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment Expected tax credit Tax expense (income) at applicable tax rate Estimated Allocation Date Two Estimated Allocation Date Two [Member] Estimated Allocation Date Two Foreign exchange forward contracts Derivative financial liabilities Other comprehensive income / (loss), net of tax Other comprehensive income (loss) Other comprehensive income Disclosure Of Financial Assets And Liabilities [Line Items] Disclosure Of Financial Assets And Liabilities [Line Items] Disclosure Of Financial Assets And Liabilities [Line Items] Prof. Ugur Sahin, M.D. Professor Ugur Sahin MD [Member] Professor Ugur Sahin MD Disclosure of fair value measurement of assets Disclosure of fair value measurement of assets [text block] Contract liabilities at beginning of period As of December 31 Contract liabilities Contract liabilities Forfeited, share options (in shares) Number of share options forfeited in share-based payment arrangement Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets Adjustments for depreciation and amortisation expense Grants Government Grants [Member] Government Grants Geographical [Axis] Geographical [Axis] Deviation due to local tax basis Tax Effect Of Deviation Due To Local Tax Basis Tax Effect Of Deviation Due To Local Tax Basis Tax losses / tax credits Unused tax credits [member] Contingent consideration Contingent consideration [member] Summary of Inventories Disclosure Of Classes Of Inventories Explanatory [Table Text Block] Disclosure Of Classes Of Inventories Explanatory Percentage of exercise price increase (as a percent) Percentage Of Increase In Exercise Price Percentage Of Increase In Exercise Price Earnings per share [table] Earnings per share [table] Other financial assets Other Financial Assets [Member] Other Financial Assets Percentage of voting equity interests acquired (as a percent) Percentage of voting equity interests acquired Other (incl. deferred expenses) Other Deferred Taxes [Member] Other Deferred Taxes InstaDeep DE GmbH InstaDeep DE GmbH [Member] InstaDeep DE GmbH General and administrative expenses General And Administrative Expenses [Member] General And Administrative Expenses Summary of Information about Parent Company Disclosure Of Significant Investments By Parent Company Explanatory [Table Text Block] Disclosure Of Significant Investments By Parent Company Explanatory Income Tax Disclosure of income tax [text block] Key management personnel compensation, severance Key management personnel compensation, Severance Key management personnel compensation, Severance Total finance result Finance Income (Expense) Finance Income (Expense) Cumulative depreciation and impairment charges Accumulated depreciation, amortisation and impairment [member] Levels of fair value hierarchy [domain] Levels of fair value hierarchy [domain] Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049 Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities Range [axis] Range [axis] Financial liabilities subsequently not measured according to IFRS 9 Financial liabilities subsequently not measured according to IFRS 9 [Member] Financial liabilities subsequently not measured according to IFRS 9 Disclosure of Other Operating Result Disclosure Of Other Operating Result [Table Text Block] Disclosure Of Other Operating Result Income and Expenses Disclosure Of Income And Expense Explanatory [Text Block] Disclosure Of Income And Expense Explanatory Other Other provisions Shares outstanding (in shares) Number of other equity instruments outstanding in share-based payment arrangement Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [table] Product and Service [Domain] Product and Service [Domain] Statement of changes in equity [line items] Statement of changes in equity [line items] Summary of Other Assets Disclosure Of Detailed Information About Other Assets Explanatory [Table Text Block] Disclosure Of Detailed Information About Other Assets Explanatory Contract liabilities As of January 1 As of December 31 Current contract liabilities Total Contract Assets [Roll Forward] Contract Assets Statement of cash flows [abstract] Current income taxes Current tax expense (income) Reclassification from non-current to current Reclassification From Non-Current To Current, Contract Assets Reclassification From Non-Current To Current, Contract Assets Security Exchange Name Security Exchange Name Contact Personnel Email Address Contact Personnel Email Address LTI 2021 program Employee Equity Plan, Long-Term Incentive 2021 Program [Member] Employee Equity Plan, Long-Term Incentive 2021 Program Proceeds from maturity of other financial assets (Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities (Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Domain] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Domain] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount Tax rate effect Tax rate effect from change in tax rate Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations Earnings per share [text block] BioNTech 2020 Employee Equity Plan for Employees Based Outside North America BioNTech Employee Equity Plan For Employees Based In Europe [Member] BioNTech Employee Equity Plan For Employees Based In Europe Beginning balance, weighted-average exercise price (in euros per share) Ending balance, weighted-average exercise price (in euros per share) Weighted average exercise price of share options outstanding in share-based payment arrangement Estimated Allocation Date Six Estimated Allocation Date Six [Member] Estimated Allocation Date Six Contract assets As of January 1 As of December 31 Current contract assets Statement of financial position [abstract] Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] Unrealized (gain) / loss on derivative instruments at fair value through profit or loss Gains (losses) on financial liabilities at fair value through profit or loss Other non-financial liabilities related to funds received based on government grants and similar grants Other Non-Financial Liabilities Related To Funds Received Based On Government Grants And Similar Grants Other Non-Financial Liabilities Related To Funds Received Based On Government Grants And Similar Grants Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Acquisition of subsidiaries and businesses Acquisitions through business combinations, property, plant and equipment Employee Stock Ownership Plan (ESOP) Name [Domain] Employee Stock Ownership Plan (ESOP) Name [Domain] Employee Stock Ownership Plan (ESOP) Name [Domain] ATHOS KG ATHOSKG [Member] ATHOSKG Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Reverse Repo Reverse Repo [Member] Reverse Repo Intellectual property rights Intellectual Property Rights [Member] Intellectual Property Rights Decrease in inventories Adjustments for decrease (increase) in inventories Solidarity surcharge rate (as a percent) Solidarity Surcharge Rate Solidarity Surcharge Rate Deferred tax liabilities Deferred tax liabilities Business Combinations Disclosure of business combinations [text block] BioNTech Innovative Manufacturing Services GmbH BioNTech Innovative Manufacturing Services GmbH [Member] BioNTech Innovative Manufacturing Services GmbH Major business combination Major business combination [member] Trade and other receivables Trade and other current receivables Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Total for all subsidiaries Total for all subsidiaries [member] Granted, share options (in shares) Granted, share options (in shares) Number of share options granted in share-based payment arrangement Concessions, licenses and similar rights Concessions, Licenses And Similar Rights [Member] Concessions, Licenses And Similar Rights BioNTech R&D (Austria) GmbH BioNTech R&D (Austria) GmbH [Member] BioNTech R&D (Austria) GmbH Unobservable inputs [axis] Unobservable inputs [axis] Summary of Changes in Liabilities Arising from Financing Activities Disclosure of reconciliation of liabilities arising from financing activities [text block] BioNTech 2024 North America Employee Participation Plan - PSUs BioNTech 2024 North America Employee Participation Plan - PSUs [Member] BioNTech 2024 North America Employee Participation Plan - PSUs LTI 2020 program Employee Equity Plan, Long-Term Incentive 2020 Program [Member] Employee Equity Plan, Long-Term Incentive 2020 Program InstaDeep Nigeria Limited InstaDeep Nigeria Limited [Member] InstaDeep Nigeria Limited BioNTech BioNTainer Holding GmbH BioNTech BioNTainer Holding GmbH [Member] BioNTech BioNTainer Holding GmbH Treasury shares used for acquisition of business combination Treasury Shares Used For Acquisition Of Business Combination Treasury Shares Used For Acquisition Of Business Combination National Institutes of Health National Institutes of Health [Member] National Institutes of Health Litigation costs Litigation Costs [Member] Litigation Costs Research and development expense (as a percent) Percentage Of Research And Development Expense Percentage Of Research And Development Expense Non-listed equity investments Non-Listed Equity Investments [Member] Non-Listed Equity Investments Entity Voluntary Filers Entity Voluntary Filers Cash outflow for share based payment exercise Cash Outflow For Share Based Payment Arrangement Exercise Cash Outflow For Share Based Payment Arrangement Exercise Deferred tax liabilities have not been recognized Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised Inventories Inventories 1 [Member] Inventories 1 Disclosure of reserves within equity [table] Disclosure of reserves within equity [table] Disclosure of detailed information about business combination [table] Disclosure of detailed information about business combination [table] thereof allocated and vested but subject to performance and waiting requirements (in shares) Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement New leases and disposals Increase through new leases, liabilities arising from financing activities Summary of Standards Issued but Not Yet Effective Disclosure of expected impact of initial application of new standards or interpretations [text block] General and administrative expense (as a percent) Percentage Of General And Administrative Expense Percentage Of General And Administrative Expense Entity Address, Country Entity Address, Country Current and deferred taxes Current And Deferred Tax Expense (Income) Current And Deferred Tax Expense (Income) Total cash outflow for leases Cash outflow for leases BioNTech Collaborations GmbH BioNTech Collaborations GmbH [Member] BioNTech Collaborations GmbH Entity Listings [Table] Entity Listings [Table] More than 5 years Later than five years [member] Decrease cost of sales Increase (Decrease) Cost Of Sales Increase (Decrease) Cost Of Sales American Depositary Shares, each Representing one ordinary share American Depositary Shares Each Representing One Ordinary Share [Member] American Depositary Shares Each Representing One Ordinary Share Other non-financial assets Total current Other current non-financial assets Summary of Financial Assets at Amortized Cost and at Fair Value through Profit or Loss Disclosure of financial assets [text block] Share-based Payment Arrangements [Abstract] Share-based Payment Arrangements [Abstract] Share-based Payment Arrangements [Abstract] Fair Value Through Profit Or Loss Fair Value Through Profit Or Loss [Member] Fair Value Through Profit Or Loss Federal corporate income tax (as a percent) Federal Corporate Income Tax Federal Corporate Income Tax Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Events After Reporting Period [Abstract] Events After Reporting Period [Abstract] Events After Reporting Period [Abstract] Document Annual Report Document Annual Report Currency effects Currency Effects Of Current Contract Liabilities Currency Effects Of Current Contract Liabilities Employee Stock Ownership Plan 2019 Employee Stock Ownership Plan 2019 [Member] Employee Stock Ownership Plan 2019 BioNTech Sénégal Suarl BioNTech Sénégal Suarl [Member] BioNTech Sénégal Suarl Audit Information [Abstract] Audit Information Trade payables and other payables Trade Payables And Other Payables [Member] Trade Payables And Other Payables Inventory write-offs Inventory write-down Cash at banks and on hand Cash Disclosure of financial liabilities [line items] Disclosure of financial liabilities [line items] Remaining upfront fees contract liabilities Remaining Upfront Fees Contract Liabilities Remaining Upfront Fees Contract Liabilities Revenues from Contracts with Customers Disclosure of revenue from contracts with customers [text block] Current Fiscal Year End Date Current Fiscal Year End Date Impairment of Non-Financial Assets Description of accounting policy for impairment of non-financial assets [text block] Currency differences Currency differences Increase (decrease) through net exchange differences, intangible assets and goodwill Awards paid at end of month settled Percentage Of American Depository Shares To Ordinary Shares, Awards Settled At End Of Month Percentage Of American Depository Shares To Ordinary Shares, Awards Settled At End Of Month Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods Other comprehensive income that will be reclassified to profit or loss, net of tax Leases [Abstract] Leases 1 [Abstract] Leases 1 Revenue recognition applying the sales-based or usage-based royalty recognition constraint model Sales Based Or Usage Based Royalty Recognition Constraint Model [Member] Sales Based Or Usage Based Royalty Recognition Constraint Model thereof: attributable to performance obligations satisfied in prior periods Non-Current Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Non-Current Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods BioNTech 2024 North America Employee Participation Plan - RSUs BioNTech 2024 North America Employee Participation Plan - RSUs [Member] BioNTech 2024 North America Employee Participation Plan - RSUs Goodwill Goodwill [member] Key management personnel compensation, severance additional payment Key management personnel compensation, Severance Additional Payment Key management personnel compensation, Severance Additional Payment Title and Position [Domain] Title and Position [Domain] Entity Interactive Data Current Entity Interactive Data Current Decrease in trade and other receivables, contract assets and other assets Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets Retained earnings Retained earnings Summary of Useful Lives Applied to the Group's Intangible Assets Disclosure of detailed information about intangible assets [text block] Key management personnel compensation, consultancy agreement payment Key management personnel compensation, Consultancy Agreement Payment Key management personnel compensation, Consultancy Agreement Payment Disclosure of terms and conditions of share-based payment arrangement [line items] Disclosure of terms and conditions of share-based payment arrangement [line items] BioNTech BioNTech [Member] BioNTech Purchases of property and other assets from entities controlled by ATHOS KG Purchases of property and other assets, related party transactions Categories of financial liabilities [domain] Categories of financial liabilities [domain] Changes in scope of consolidation Changes In Scope Of Consolidation, Non-Current Contract Assets Changes In Scope Of Consolidation Of Non-Current Contract Assets Classes of share capital [axis] Classes of share capital [axis] Share Repurchase Program Period [Axis] Share Repurchase Program Period [Axis] Share Repurchase Program Period Disclosure of quantitative information about right-of-use assets [table] Disclosure of quantitative information about right-of-use assets [table] Liabilities arising from financing activities [axis] Liabilities arising from financing activities [axis] Summary of Standards Applied for the First Time Disclosure of initial application of standards or interpretations [text block] Austria AUSTRIA Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Non-current liabilities Non-current liabilities [abstract] Research And Development [Member] Research And Development [Member] Research And Development Purchases of various goods and services from entities controlled by ATHOS KG Purchases Of Goods And Service Related Party Transactions Purchases Of Goods And Service Related Party Transactions Other Other Liabilities, Other Other Liabilities, Other Total Other non-financial assets Total Beginning balance Ending balance Financial assets Leases Disclosure of leases [text block] Property, plant and equipment [abstract] Property, plant and equipment [abstract] Share capital Issued capital Estimated Allocation Date Five Estimated Allocation Date Five [Member] Estimated Allocation Date Five Total amounts recognized in profit or loss Lease Expenses Recognized In Profit Or Loss Lease Expenses Recognized In Profit Or Loss Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits [Member] Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits Gains on litigation settlements Gains on litigation settlements Weighted average number of ordinary shares outstanding adjusted for the effect of dilution (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share Average rate Average foreign exchange rate Auditor Firm ID Auditor Firm ID Revenue From Contracts With Customers [Abstract] Revenue From Contracts With Customers [Abstract] Revenue From Contracts With Customers [Abstract] Total assets Assets Less than 1 year Not later than one year [member] Expense arising from equity-settled share-based payment arrangements Expense from equity-settled share-based payment transactions Medilink Therapeutics (Suzhou) Co. Ltd., Medilink Therapeutics (Suzhou) Co. Ltd., [Member] Medilink Therapeutics (Suzhou) Co. Ltd., Proceeds from issuance of share capital and treasury shares, net of costs Proceeds from issuing shares Net employee defined benefit liabilities Net Employee Defined Benefit Liabilities [Member] Net Employee Defined Benefit Liabilities Effect on pre-tax equity Foreign Currency Changes Effect On Pretax Equity Foreign Currency Changes Effect On Pretax Equity BioNTech Switzerland GmbH BioNTech Switzerland GmbH [Member] BioNTech Switzerland GmbH Loss from financial instruments measured at fair value Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Fair Value Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Fair Value Disclosure of detailed information about intangible assets [line items] Disclosure of detailed information about intangible assets [line items] Management Board Grant Management Board Grant [Member] Management Board Grant Capital reserve Capital reserve [member] Reclassification from non-current to current Reclassification From Non-Current To Current, Current Contract Assets Reclassification From Non-Current To Current, Current Contract Assets Deferred tax assets Deferred tax assets European Commission To Collaboration Partner European Commission To Collaboration Partner [Member] European Commission To Collaboration Partner Lease liabilities, loans and borrowings Non-current Lease Liabilities, Loans And Borrowings Non-current Lease Liabilities, Loans And Borrowings Classes of financial assets Classes of financial assets [domain] thereof un-vested, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement Disclosure of reconciliation of changes in intangible assets and goodwill [table] Disclosure of reconciliation of changes in intangible assets and goodwill [table] Product and Service [Axis] Product and Service [Axis] Miscellaneous Miscellaneous [Member] Miscellaneous Option rights vesting period (in years) Option Vesting Period Option Vesting Period Impairment loss for a reduction of future cash flows (as a percent) Percentage Of Impairment Loss For A Reduction Of Future Cash Flows Percentage Of Impairment Loss For A Reduction Of Future Cash Flows Disclosure of quantitative information about right-of-use assets [line items] Disclosure of quantitative information about right-of-use assets [line items] Range [domain] Range [domain] Other Non-Financial Assets [Abstract] Other Non-Financial Assets Exercise price of phantom options granted (in euro per share) Exercise Price, Phantom Options Granted Exercise Price, Phantom Options Granted Summary of Accumulated Tax Losses Disclosure Of Accumulated Tax Losses Explanatory [Table Text Block] Disclosure Of Accumulated Tax Losses Explanatory Other comprehensive income Other comprehensive income [abstract] Basic earnings for the period per share (in euros per share) Basic profit for the period per share (in euros per share) Basic earnings (loss) per share Chief Executive Officer Grant Chief Executive Officer Grant [Member] Chief Executive Officer Grant Duality Biologics (Suzhou) Co. Ltd., Duality Biologics (Suzhou) Co. Ltd., [Member] Duality Biologics (Suzhou) Co. Ltd., Closing rate Closing foreign exchange rate Financing activities Cash flows from (used in) financing activities [abstract] Summary of Number and Share Price of Restricted Stock Units Disclosure of number and weighted average exercise prices of other equity instruments [text block] Other Non-Financial Liabilities Disclosure of other liabilities [text block] United Kingdom UNITED KINGDOM Segment Information Description of accounting policy for segment reporting [text block] Timing of transfer of goods or services Timing of transfer of goods or services [domain] Sales and marketing expense (as a percent) Percentage Of Sales And Marketing Expense Percentage Of Sales And Marketing Expense thereof un-vested, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement % equity interest Ownership of ordinary shares in BioNTech (in %) Proportion of ownership interest in subsidiary Non tax-effective income Tax Effect, Non Tax Effective Income Tax Effect, Non Tax Effective Income Other Non-Financial Assets Disclosure of other assets [text block] Classes of share capital Classes of share capital [domain] Classes of liabilities Classes of liabilities [domain] InstaDeep Ltd. InstaDeep Ltd. [Member] InstaDeep Ltd. Supervisory Board Supervisory Board [Member] Supervisory Board Inventories [Abstract] Inventories [Abstract] Inventories [Abstract] Liabilities to employees Liabilities For Employee Benefits Liabilities For Employee Benefits (Gain) / Loss on disposal of property, plant and equipment Adjustments for gain (loss) on disposals, property, plant and equipment LTI Program Employee Equity Plan, Long-Term Incentive Program [Member] Employee Equity Plan, Long-Term Incentive Program Tax-effective equity transaction costs Tax Effective Equity Transaction Costs Tax Effective Equity Transaction Costs Basis of Consolidation Disclosure of basis of consolidation [text block] Contingent liabilities and other financial commitments Disclosure of commitments and contingent liabilities [text block] BioNTech US Inc. BioNTech US Inc. [Member] BioNTech US Inc. Estimated Allocation Date Three Estimated Allocation Date Three [Member] Estimated Allocation Date Three Monetary assets in U.S. dollar Monetary Assets [Member] Monetary Assets Forfeited, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement Other non-financial assets Total non-current Other non-current non-financial assets Cash flow projections Cash Flow Projections, Measurement Input [Member] Cash Flow Projections, Measurement Input Contract Liabilities Contract Liabilities [Table Text Block] Contract Liabilities Contract liabilities As of January 1 As of December 31 Non-current contract liabilities Forfeited (in shares) Number of other equity instruments forfeited in share-based payment arrangement BioNTech Manufacturing Marburg GmbH BioNTech Manufacturing Marburg GmbH [Member] BioNTech Manufacturing Marburg GmbH Disclosure Of Income And Expenses [Line Items] Disclosure Of Income And Expenses [Line Items] Disclosure Of Income And Expenses Net change in fair value Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities InstaDeep LLC InstaDeep LLC [Member] InstaDeep LLC State income tax with average rate (as a percent) Effective tax rate Average effective tax rate Disposals Sales, fair value measurement, assets Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Useful life measured as period of time, intangible assets other than goodwill (in years) Useful life measured as period of time, intangible assets other than goodwill Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements Disclosure of significant unobservable inputs used in fair value measurement of assets [text block] Contractual disputes / settlements Contractual Disputes And Settlements [Member] Contractual Disputes And Settlements Address Type [Domain] Address Type [Domain] Corporate Information Disclosure Of Corporate Information Explanatory [Text Block] Disclosure Of Corporate Information Explanatory Cash and cash equivalents in U.S. dollar Cash And Cash Equivalents 1 [Member] Cash And Cash Equivalents 1 Change in fair value with decreasing input factor (in millions €) Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities Income And Expenses By Nature [Domain] Income And Expenses By Nature [Domain] Income And Expenses By Nature [Domain] Summary of Shares Repurchase Program Disclosure of Shares Repurchase Program [Table Text Block] Disclosure of Shares Repurchase Program Operating profit / (loss) Profit (loss) from operating activities Income tax paid Income taxes paid (refund), classified as operating activities Government grants Adjustments For Movements In Government Grants Adjustments For Movements In Government Grants Recognized in OCI Deferred Tax Expense (Income) Recognised In Other Comprehensive Income Deferred Tax Expense (Income) Recognised In Other Comprehensive Income Additions to right-of-use assets Additions to right-of-use assets Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Finance expenses Finance expenses Finance costs Number of share options held (in shares) Number Of Share Options Held Number Of Share Options Held Share-Based Payment Arrangements Share-Based Payment Arrangements [Member] Share-Based Payment Arrangements Reclassification from non-current to current Reclassification From Non-Current To Current, Current Contract Liabilities Reclassification From Non-Current To Current, Current Contract Liabilities Investing activities Cash flows from (used in) investing activities [abstract] Profit attributable to ordinary equity holders of the parent for basic earnings Profit (loss), attributable to owners of parent Deferred tax (assets) and liabilities, net recognized Beginning balance deferred tax assets net Ending balance deferred tax assets net Deferred tax liability (asset) Fair Value Through OCI Fair Value Through OCI [Member] Fair Value Through OCI Thereof deferred tax assets Thereof Deferred Tax Assets [Member] Thereof Deferred Tax Assets Inventories Disclosure of inventories [text block] Germany GERMANY Non-current Non-current lease liabilities Net cash flows used in financing activities Cash flows from (used in) financing activities Non-current assets Non-current assets [abstract] Earnings / (Loss) per share Basic earnings per share [abstract] Summary of Other Non-Financial Liabilities Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory [Table Text Block] Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory Trade and other payables Trade and other payables Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets Summary of Right-of-Use Assets within Consolidated Statements of Financial Position Disclosure of quantitative information about right-of-use assets [text block] Liabilities from share-based payment arrangements Liabilities from share-based payment transactions Equity Equity [abstract] Estimated Allocation Date Four Estimated Allocation Date Four [Member] Estimated Allocation Date Four No Trading Symbol Flag No Trading Symbol Flag Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [axis] Additional provisions, other provisions Additional provisions, other provisions Consolidated structured entities [axis] Consolidated structured entities [axis] Business combinations Business combinations [domain] Lease liabilities, loans and borrowings Current Lease Liabilities, Loans And Borrowings Current Lease Liabilities, Loans And Borrowings BioNTech Rwanda Ltd. BioNTech Rwanda Ltd. [Member] BioNTech Rwanda Ltd. Entity Emerging Growth Company Entity Emerging Growth Company Estimated Allocation Date One Estimated Allocation Date One [Member] Estimated Allocation Date One Summary of Other Operating Income Disclosure Of Other Operating Income Explanatory [Table Text Block] Disclosure Of Other Operating Income Explanatory Current onerous provision addition Current Onerous Contracts Provision, Additions Current Onerous Contracts Provision, Additions Disclosure of transactions between related parties [table] Disclosure of transactions between related parties [table] Equity and liabilities Equity and liabilities [abstract] Contingent consideration Contingent liabilities recognised in business combination Business Contact Business Contact [Member] Licenses Licences [member] Effects from tax losses and tax credits Tax effect of tax losses Equipment, tools and installations Equipment, Tools And Installations [Member] Equipment, Tools And Installations Liquidity risk Liquidity risk [member] Jens Holstein Jens Holstein [Member] Jens Holstein Pfizer Inc. Pfizer Inc [Member] Pfizer Inc Summary of Information about Subsidiaries Disclosure of subsidiaries [text block] Financial Instruments [Abstract] Financial Instruments [Abstract] Financial Instruments [Abstract] NT Security and Services GmbH NT Security and Services GmbH [Member] NT Security and Services GmbH Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings Disclosure Of Detailed Information About Lease Liabilities Explanatory [Table Text Block] Disclosure Of Detailed Information About Lease Liabilities Explanatory Fair Value Measurement Description of accounting policy for fair value measurement [text block] Other Increase (decrease) through other changes, liabilities arising from financing activities Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Trade and other receivables Trade And Other Receivables [Member] Trade And Other Receivables Non-adjusting events after reporting period Non-adjusting events after reporting period [domain] Buildings Buildings [member] Net other comprehensive income / (loss) that will not be reclassified to profit or loss in subsequent periods Other comprehensive income that will not be reclassified to profit or loss, net of tax Net foreign exchange differences Adjustments for unrealised foreign exchange losses (gains) Counterparty Name [Axis] Counterparty Name [Axis] Other operating expenses Miscellaneous other operating expense JPT Peptide Technologies GmbH JPT Peptide Technologies GmbH [Member] JPT Peptide Technologies GmbH Other reserves Other reserves Categories of related parties [axis] Categories of related parties [axis] Security Investments Disclosed As Other Financial Assets Security Investments Disclosed As Other Financial Assets [Member] Security Investments Disclosed As Other Financial Assets Summary of Current and Deferred Tax Expense Disclosure Of Current And Deferred Tax Expense Explanatory [Table Text Block] Disclosure Of Current And Deferred Tax Expense Explanatory Maximum economic benefits of options exercised Maximum Economic Benefits Of Options Exercised Maximum Economic Benefits Of Options Exercised Right-of-use assets Right-of-use assets [member] Income And Expenses By Nature [Axis] Income And Expenses By Nature [Axis] Income And Expenses By Nature Deferred expenses Deferred Expense Deferred Expense Cash-settled related to rights vested and exercisable Share Based Payment Arrangement, Related To Rights Vested And Exercisable Share Based Payment Arrangement, Related To Rights Vested And Exercisable Cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents as of December 31 Total Cash and cash equivalents Financial Instruments Description of accounting policy for financial instruments [text block] Right-of-use assets, useful life (in years) Useful Life Measured As Period Of Time, Right-Of-Use Assets Useful Life Measured As Period Of Time, Right-Of-Use Assets BioNTech 2020 Restricted Stock Unit Plan for North America Employees BioNTech 2020 Restricted Stock Unit Plan For North America Employees BioNTech 2020 Restricted Stock Unit Plan For North America Employees [Member] BioNTech 2020 Restricted Stock Unit Plan For North America Employees Number of ordinary shares underlying options Number Of Ordinary Shares Underlying Options [Abstract] Number Of Ordinary Shares Underlying Options Liabilities [Roll Forward] Liabilities [Roll Forward] Liabilities Non-tax effective bargain purchase Non Tax Effective Bargain Purchase Non Tax Effective Bargain Purchase Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share options outstanding Share Options Outstanding [Abstract] Share Options Outstanding Standards Applied for the First Time Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory [Policy Text Block] Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory Foreign exchange forward contracts Forward contract [member] Maturity [axis] Maturity [axis] Costs of inventories Cost of inventories recognised as expense during period Fair value measurement derivative Accumulated increase (decrease) in fair value of credit derivatives or similar instruments related to financial assets designated as measured at fair value through profit or loss Contingent consideration recognised as of acquisition date Contingent consideration recognised as of acquisition date Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [table] Percentage of entity's revenue Percentage of entity's revenue Unobservable inputs [domain] Unobservable inputs [domain] Repayment of loans and borrowings Repayments of borrowings, classified as financing activities Goods and services transferred at a point in time Goods or services transferred at point in time [member] Outstanding balances of related party transactions Provisions for doubtful debts related to outstanding balances of related party transaction Disposals Sales, fair value measurement, liabilities Currency differences Increase (decrease) through net exchange differences, property, plant and equipment Number of shares outstanding (in shares) Number of shares outstanding Disclosure of subsidiaries [line items] Disclosure of subsidiaries [line items] Inventories Description of accounting policy for measuring inventories [text block] Inventories Total Current inventories Operating activities Cash flows from (used in) operating activities [abstract] Entity Registrant Name Entity Registrant Name Interest on lease liabilities Interest expense on lease liabilities Thereof deferred tax liability Thereof Deferred Tax Liability [Member] Thereof Deferred Tax Liability Income tax assets Current tax assets, current Categories of financial liabilities [axis] Categories of financial liabilities [axis] Share Capital, Reserves and Other Equity Interest [Abstract] Share Capital, Reserves and Other Equity Interest [Abstract] Share Capital, Reserves and Other Equity Interest [Abstract] Total Employee benefits expense Current Current financial assets Geographical [Domain] Geographical [Domain] Change in fair value with increasing input factor (in millions €) Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities Exercised, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement Maturity Maturity [domain] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Title of 12(b) Security Title of 12(b) Security Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [axis] Document Financial Statement Error Correction Document Financial Statement Error Correction [Flag] Recognition as revenues Non-Current Contract Liabilites Recognized As Revenue Non-Current Contract Liabilites Recognized As Revenue Risk-free interest rate Risk free interest rate, share options granted Share repurchase program Share Repurchase Program, Repurchased During Period, Value Share Repurchase Program, Repurchased During Period, Value Summary of Estimated Useful Lives of the Assets or Shorter Lease Term Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory [Table Text Block] Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory Recognition as revenues Current Contract Liabilites Recognized As Revenue Current Contract Liabilites Recognized As Revenue Biotheus Inc., Biotheus Inc., [Member] Biotheus Inc., Related Party Disclosures Disclosure of related party [text block] Reclassification to trade accounts receivables Reclassification Io Trade Accounts Receivables, Current Contract Assets Reclassification Io Trade Accounts Receivables, Current Contract Assets Disclosure of detailed information about property, plant and equipment [line items] Disclosure of detailed information about property, plant and equipment [line items] Summary of Carrying Amount of Monetary Assets Disclosure Of Foreign Currency Risk Explanatory [Table Text Block] Disclosure Of Foreign Currency Risk Explanatory All Currencies [Domain] All Currencies [Domain] Employee Stock Ownership Plan Employee Stock Ownership Plan [Member] Employee Stock Ownership Plan Interests In Other Entities [Abstract] Interests In Other Entities [Abstract] Interests In Other Entities [Abstract] Upfront payment Upfront Payment Upfront Payment Investment in other financial assets Other cash payments to acquire interests in joint ventures, classified as investing activities Ownership [Domain] Ownership [Domain] Related Party [Abstract] Related Party [Abstract] Related Party [Abstract] Government Grants Received Government Grants Received Government Grants Received Number of ADSs purchased (in shares) Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased Acquisition of subsidiaries and businesses, net of cash acquired Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities Maximum Top of range [member] Total Cash And Cash Equivalent Cash And Cash Equivalent Current Current lease liabilities Reclassification to trade accounts receivables Reclassification Io Trade Accounts Receivables, Non-Current Contract Assets Reclassification Io Trade Accounts Receivables, Non-Current Contract Assets Summary of Effect of Changes in Foreign Exchange Rates Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory [Table Text Block] Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory Proceeds from loans and borrowings Proceeds from borrowings, classified as financing activities Other financial assets Other current financial assets BioNTech Delivery Technologies (US), LLC BioNTech Delivery Technologies (US), LLC [Member] BioNTech Delivery Technologies (US), LLC LTI 2022 program Employee Equity Plan, Long-Term Incentive 2022 Program [Member] Employee Equity Plan, Long-Term Incentive 2022 Program Share Repurchase Program 2023 Share Repurchase Program 2023 [Member] Share Repurchase Program 2023 Revenues Revenue from contracts with customers Entity Address, City or Town Entity Address, City or Town Gains from financial instruments measured at amortized cost Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Financial Assets and Financial Liabilities Disclosure of offsetting of financial assets and financial liabilities [text block] Disclosure Of Financial Assets And Liabilities [Table] Disclosure Of Financial Assets And Liabilities [Table] Disclosure Of Financial Assets And Liabilities [Table] Total Purchases From Related Party Transactions Purchases From Related Party Transactions Monetary liabilities and provisions in U.S. dollar Monetary Liability And Provisions [Member] Monetary Liability And Provisions Cash flows Increase (decrease) through financing cash flows, liabilities arising from financing activities Exercised, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement General and administrative expenses General and administrative expenses General and administrative expense Fringe benefits Key Management Personnel Compensation, Fringe Benefits Key Management Personnel Compensation, Fringe Benefits Group Information Disclosure of composition of group [text block] Share capital Issued capital [member] thereof vested, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement Purchase of property, plant and equipment Purchase of property, plant and equipment, classified as investing activities Document Fiscal Year Focus Document Fiscal Year Focus Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine [Member] Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Document Period End Date Document Period End Date Loss from financial instruments measured at amortized cost without expected credit losses Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Without Expected Credit Losses Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Without Expected Credit Losses Effects of dilution from share options (in shares) Dilutive effect of share options on weighted average number of ordinary shares Share-based payment expenses Adjustments for share-based payments Additions Increase (Decrease) In Current Contract Liabilities Increase (Decrease) In Current Contract Liabilities Additions Purchases, fair value measurement, liabilities Current versus Non-Current Classifications Description Of Accounting Policy For Assets And Liabilities Explanatory [Policy Text Block] Description Of Accounting Policy For Assets And Liabilities Explanatory Amortization Accumulated Depreciation, Amortisation And Impairment Accumulated Depreciation, Amortisation And Impairment Change in deferred taxes due to tax rate change Tax effect from change in tax rate Total non-current assets Total non-current assets Non-current assets Comprehensive income / (loss), net of tax Comprehensive income Issuance of share capital Issuance Of Share Capital Issuance Of Share Capital Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Cost of sales (as a percent) Percentage Of Cost Of Sales Percentage Of Cost Of Sales Document Transition Report Document Transition Report Income Taxes [Abstract] Income Taxes [Abstract] Income Taxes [Abstract] Reclassification from non-current to current Reclassification From Non-Current To Current, Non-Current Contract Assets Reclassification From Non-Current To Current, Non-Current Contract Assets Summary of Deferred Taxes Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Entity Current Reporting Status Entity Current Reporting Status Automobiles Vehicles [member] Weighted average cost of capital (as a percent) Capitalisation rate of borrowing costs eligible for capitalisation Effect on profit / (loss) before tax Foreign Currency Changes Effect On Loss, Before Tax Foreign Currency Changes Effect On Loss, Before Tax Net increase / (decrease) in cash and cash equivalents Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Bank deposits Bank Deposits [Member] Bank Deposits Consideration transferred, acquisition-date fair value Consideration transferred, acquisition-date fair value Share-Based Payments Disclosure of share-based payment arrangements [text block] BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi [Member] BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi Liabilities from wage taxes and social securities expenses Liabilities From Wage Taxes And Social Securities Expenses Liabilities From Wage Taxes And Social Securities Expenses Growth rate used to extrapolate cash flow projections (as a percent) Growth rate used to extrapolate cash flow projections OncoC4 Inc. OncoC4 Inc. [Member] OncoC4 Inc. UPenn UPenn [Member] UPenn Income tax liabilities Current tax liabilities, current